17 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
RPR203494 a pyrimidine analogue of the p38 inhibitor RPR200765A with an improved in vitro potency.
Aventis Pharma
Fine Tuning of physico-chemical parameters to optimise a new series of novobiocin analogues.
Aventis Pharma
Principles governing the binding of a class of non-peptidic inhibitors to the SH2 domain of src studied by X-ray analysis.
Aventis Pharma
Design and synthesis of bridged gamma-lactams as analogues of beta-lactam antibiotics.
Aventis Pharma
Structural requirements for inhibition of the neuronal nitric oxide synthase (NOS-I): 3D-QSAR analysis of 4-oxo- and 4-amino-pteridine-based inhibitors.
Aventis Pharma
Small ligands interacting with the phosphotyrosine binding pocket of the Src SH2 protein.
Aventis Pharma
Discovery of highly potent Src SH2 binders: structure-activity studies and X-ray structures.
Aventis Pharma
Discovery of an orally active non-peptide fibrinogen receptor antagonist based on the hydantoin scaffold.
Aventis Pharma
Synthesis of analogues of the O-beta-D-ribofuranosyl nucleoside moiety of liposidomycins. Part 1: contribution of the amino group and the uracil moiety upon the inhibition of MraY.
Aventis Pharma
Solid-phase optimisation of achiral amidinobenzyl indoles as potent and selective factor Xa inhibitors.
Aventis Pharma
An algorithm-directed two-component library synthesized via solid-phase methodology yielding potent and orally bioavailable p38 MAP kinase inhibitors.
Aventis Pharma
Chiral Recognition Thermodynamics of β-Cyclodextrin: The Thermodynamic Origin of Enantioselectivity and the Enthalpy-Entropy Compensation Effect
Japan Science and Technology Agency
Structure-activity relationship of HIV-1 protease inhibitors containing alpha-hydroxy-beta-amino acids. Detailed study of P1 site.
Sankyo